BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

522 related articles for article (PubMed ID: 18440229)

  • 21. A series of novel, potent, and selective histone deacetylase inhibitors.
    Jones P; Altamura S; Chakravarty PK; Cecchetti O; De Francesco R; Gallinari P; Ingenito R; Meinke PT; Petrocchi A; Rowley M; Scarpelli R; Serafini S; Steinkühler C
    Bioorg Med Chem Lett; 2006 Dec; 16(23):5948-52. PubMed ID: 16987657
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Identification of ligand features essential for HDACs inhibitors by pharmacophore modeling.
    Chen YD; Jiang YJ; Zhou JW; Yu QS; You QD
    J Mol Graph Model; 2008 Apr; 26(7):1160-8. PubMed ID: 18061500
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Class II-selective histone deacetylase inhibitors. Part 2: alignment-independent GRIND 3-D QSAR, homology and docking studies.
    Ragno R; Simeoni S; Rotili D; Caroli A; Botta G; Brosch G; Massa S; Mai A
    Eur J Med Chem; 2008 Mar; 43(3):621-32. PubMed ID: 17698257
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Determination of the class and isoform selectivity of small-molecule histone deacetylase inhibitors.
    Khan N; Jeffers M; Kumar S; Hackett C; Boldog F; Khramtsov N; Qian X; Mills E; Berghs SC; Carey N; Finn PW; Collins LS; Tumber A; Ritchie JW; Jensen PB; Lichenstein HS; Sehested M
    Biochem J; 2008 Jan; 409(2):581-9. PubMed ID: 17868033
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Synthesis, biological evaluation, and molecular docking of Ugi products containing a zinc-chelating moiety as novel inhibitors of histone deacetylases.
    Grolla AA; Podestà V; Chini MG; Di Micco S; Vallario A; Genazzani AA; Canonico PL; Bifulco G; Tron GC; Sorba G; Pirali T
    J Med Chem; 2009 May; 52(9):2776-85. PubMed ID: 19344175
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Zinc binding in HDAC inhibitors: a DFT study.
    Wang D; Helquist P; Wiest O
    J Org Chem; 2007 Jul; 72(14):5446-9. PubMed ID: 17579460
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Design and campaign synthesis of piperidine- and thiazole-based histone deacetylase inhibitors.
    Andrews DM; Stokes ES; Carr GR; Matusiak ZS; Roberts CA; Waring MJ; Brady MC; Chresta CM; East SJ
    Bioorg Med Chem Lett; 2008 Apr; 18(8):2580-4. PubMed ID: 18378449
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The crystal structures of human alpha-thrombin complexed with active site-directed diamino benzo[b]thiophene derivatives: a binding mode for a structurally novel class of inhibitors.
    Chirgadze NY; Sall DJ; Briggs SL; Clawson DK; Zhang M; Smith GF; Schevitz RW
    Protein Sci; 2000 Jan; 9(1):29-36. PubMed ID: 10739244
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Exploration of the internal cavity of histone deacetylase (HDAC) with selective HDAC1/HDAC2 inhibitors (SHI-1:2).
    Methot JL; Chakravarty PK; Chenard M; Close J; Cruz JC; Dahlberg WK; Fleming J; Hamblett CL; Hamill JE; Harrington P; Harsch A; Heidebrecht R; Hughes B; Jung J; Kenific CM; Kral AM; Meinke PT; Middleton RE; Ozerova N; Sloman DL; Stanton MG; Szewczak AA; Tyagarajan S; Witter DJ; Secrist JP; Miller TA
    Bioorg Med Chem Lett; 2008 Feb; 18(3):973-8. PubMed ID: 18182289
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Molecular design of histone deacetylase inhibitors by aromatic ring shifting in chlamydocin framework.
    Shivashimpi GM; Amagai S; Kato T; Nishino N; Maeda S; Nishino TG; Yoshida M
    Bioorg Med Chem; 2007 Dec; 15(24):7830-9. PubMed ID: 17881232
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Design of chimeric histone deacetylase- and tyrosine kinase-inhibitors: a series of imatinib hybrides as potent inhibitors of wild-type and mutant BCR-ABL, PDGF-Rbeta, and histone deacetylases.
    Mahboobi S; Dove S; Sellmer A; Winkler M; Eichhorn E; Pongratz H; Ciossek T; Baer T; Maier T; Beckers T
    J Med Chem; 2009 Apr; 52(8):2265-79. PubMed ID: 19301902
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Amino acid derivatives as histone deacetylase inhibitors.
    Hubbs JL; Zhou H; Kral AM; Fleming JC; Dahlberg WK; Hughes BL; Middleton RE; Szewczak AA; Secrist JP; Miller TA
    Bioorg Med Chem Lett; 2008 Jan; 18(1):34-8. PubMed ID: 18042381
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Trithiocarbonates: exploration of a new head group for HDAC inhibitors.
    Dehmel F; Ciossek T; Maier T; Weinbrenner S; Schmidt B; Zoche M; Beckers T
    Bioorg Med Chem Lett; 2007 Sep; 17(17):4746-52. PubMed ID: 17606370
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Synthesis and structure-activity relationship of histone deacetylase (HDAC) inhibitors with triazole-linked cap group.
    Chen PC; Patil V; Guerrant W; Green P; Oyelere AK
    Bioorg Med Chem; 2008 May; 16(9):4839-53. PubMed ID: 18397827
    [TBL] [Abstract][Full Text] [Related]  

  • 35. New pyrrole-based histone deacetylase inhibitors: binding mode, enzyme- and cell-based investigations.
    Mai A; Valente S; Nebbioso A; Simeoni S; Ragno R; Massa S; Brosch G; De Bellis F; Manzo F; Altucci L
    Int J Biochem Cell Biol; 2009 Jan; 41(1):235-47. PubMed ID: 18834955
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Trithiocarbonates as a novel class of HDAC inhibitors: SAR studies, isoenzyme selectivity, and pharmacological profiles.
    Dehmel F; Weinbrenner S; Julius H; Ciossek T; Maier T; Stengel T; Fettis K; Burkhardt C; Wieland H; Beckers T
    J Med Chem; 2008 Jul; 51(13):3985-4001. PubMed ID: 18558669
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Design and synthesis of thiazole-5-hydroxamic acids as novel histone deacetylase inhibitors.
    Anandan SK; Ward JS; Brokx RD; Denny T; Bray MR; Patel DV; Xiao XY
    Bioorg Med Chem Lett; 2007 Nov; 17(21):5995-9. PubMed ID: 17827005
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Design and campaign synthesis of pyridine-based histone deacetylase inhibitors.
    Andrews DM; Gibson KM; Graham MA; Matusiak ZS; Roberts CA; Stokes ES; Brady MC; Chresta CM
    Bioorg Med Chem Lett; 2008 Apr; 18(8):2525-9. PubMed ID: 18378451
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Stereoselective HDAC inhibition from cysteine-derived zinc-binding groups.
    Butler KV; He R; McLaughlin K; Vistoli G; Langley B; Kozikowski AP
    ChemMedChem; 2009 Aug; 4(8):1292-301. PubMed ID: 19551801
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Optimization of biaryl Selective HDAC1&2 Inhibitors (SHI-1:2).
    Witter DJ; Harrington P; Wilson KJ; Chenard M; Fleming JC; Haines B; Kral AM; Secrist JP; Miller TA
    Bioorg Med Chem Lett; 2008 Jan; 18(2):726-31. PubMed ID: 18060775
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 27.